Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

CEL-SCI’s Multikine gets Saudi fast-track designation

CEL-SCI’s Multikine gets Saudi fast-track designation

CEL-SCI's investigational cancer immunotherapy, Multikine, has received Saudi Arabia's fast-track designation under the New Accelerator Program for Drugs in Rare Diseases (NADR), a press release announced. Amarox, CEL-SCI's regulatory and commercialization partner in Saudi Arabia, submitted the designation. The company intends to file a Marketing Authorization Application with the Saudi Food and Drug Authority within the next two to three months.

The NADR program, initiated by the Saudi Food and Drug Authority in August 2026, aims to speed up the review of therapies addressing serious diseases with significant unmet medical needs. CEL-SCI plans to seek marketing authorization for patients with locally advanced, resectable oral cavity squamous cell carcinoma who have not been previously treated and have low PD-L1 expression.

A Phase 3 study showed 73% five-year overall survival with neoadjuvant treatment compared to 45% with standard care alone. Under a partnership announced in May 2026, Amarox serves as CEL-SCI's exclusive commercial distributor in Saudi Arabia, with a 50/50 net revenue-sharing model and an option to expand to other Gulf Cooperation Council member states.

Multikine, manufactured in CEL-SCI's U.S.-based facility, has administered the therapy to over 740 patients and has received Orphan Drug designation from the FDA for neoadjuvant therapy in squamous cell carcinoma of the head and neck.

Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Read the original at investing.com →